Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial

Summary Background Randomised phase 3 trials in metastatic breast cancer have shown that combining bevacizumab with either paclitaxel or capecitabine significantly improves progression-free survival and response rate compared with chemotherapy alone but the relative efficacy of bevacizumab plus pacl...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2013-02, Vol.14 (2), p.125-133
Hauptverfasser:	Lang, Istvan, Prof, Brodowicz, Thomas, MD, Ryvo, Larisa, MD, Kahan, Zsuzsanna, Prof, Greil, Richard, Prof, Beslija, Semir, MD, Stemmer, Salomon M, MD, Kaufman, Bella, MD, Zvirbule, Zanete, MD, Steger, Günther G, MD, Melichar, Bohuslav, Prof, Pienkowski, Tadeusz, MD, Sirbu, Daniela, MD, Messinger, Diethelm, MSc, Zielinski, Christoph, Prof
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - pathology Cancer therapies Capecitabine Chemotherapy Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Female Fluorouracil - administration & dosage Fluorouracil - analogs & derivatives Fluorouracil - therapeutic use Hematology, Oncology and Palliative Medicine Humans Hypotheses Metastasis Middle Aged Neoplasm Metastasis Paclitaxel - administration & dosage Paclitaxel - therapeutic use Quality of life Receptor, ErbB-2 Survival analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!